첨단 생물제제 제조 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 프로세스별, 컴포넌트별, 전개 형태별(-2035년)

Advanced Biologics Manufacturing Market is anticipated to expand from $563.0 billion in 2024 to $1,545.9 billion by 2034, growing at a CAGR of approximately 12.2%. The Advanced Biologics Manufacturing Market encompasses the production of complex biological products, including monoclonal antibodies, vaccines, and cell therapies. This market is driven by advancements in biotechnology, necessitating cutting-edge facilities and technologies for precision and scalability. Key trends include the integration of single-use systems, automation, and continuous manufacturing processes. The market is poised for growth as personalized medicine and biopharmaceutical innovations expand, requiring enhanced production capabilities and regulatory compliance.

The Advanced Biologics Manufacturing Market is experiencing robust growth, fueled by the increasing demand for personalized medicines and innovative therapies. The cell therapy segment is the top-performing sub-segment, driven by advancements in CAR-T therapies and stem cell research. Gene therapy follows closely, with significant investments in CRISPR and other gene-editing technologies enhancing therapeutic efficacy. Bioprocessing equipment and reagents are critical, supporting the production of high-quality biologics with improved scalability and efficiency. Single-use technologies are gaining prominence, offering flexibility and cost-effectiveness in manufacturing processes. The contract manufacturing organizations (CMOs) segment is expanding, as pharmaceutical companies seek to optimize resources and focus on core competencies. Continuous bioprocessing is emerging as a transformative approach, improving yields and reducing production timelines. As regulatory frameworks evolve to accommodate these innovations, the market is poised for further expansion, with a focus on sustainable and efficient manufacturing practices driving future growth.

The Advanced Biologics Manufacturing Market is experiencing a dynamic shift, marked by strategic pricing models and a surge of new product launches. Key industry players are leveraging innovative technologies to capture market share, focusing on cost-efficiency and quality enhancement. The market is seeing a trend towards personalized medicine, driving demand for advanced biologics. The introduction of novel therapeutics is reshaping competitive landscapes, with companies investing heavily in R&D to maintain a competitive edge. Competition is fierce, with leading firms benchmarking against each other to optimize production processes and reduce time-to-market. Regulatory influences, particularly in North America and Europe, are pivotal, shaping operational standards and compliance requirements. The market is characterized by a robust pipeline of biologics, driven by advancements in biotechnology and a growing emphasis on sustainable manufacturing practices. Regulatory bodies are increasingly focusing on transparency and safety, impacting market dynamics. The industry's growth is underpinned by technological innovations and strategic alliances.

Geographical Overview:

The Advanced Biologics Manufacturing Market is witnessing dynamic growth across various regions, each with unique opportunities. North America remains a leader, driven by robust research and development initiatives and substantial investments in biotechnology. The presence of major pharmaceutical companies and advanced healthcare infrastructure further propels the market. Europe follows closely, with its strong regulatory framework and emphasis on biopharmaceutical innovation. The region's commitment to sustainable and cutting-edge biologics manufacturing enhances its market position. In Asia Pacific, the market is expanding rapidly, fueled by increasing demand for biologics and government support for biotechnology. Countries like China and India are emerging as significant players due to their growing investment in healthcare infrastructure and research capabilities. Latin America and the Middle East & Africa are also gaining traction. These regions are recognizing the potential of advanced biologics manufacturing to address unmet medical needs and drive economic growth, signaling new growth pockets.

Global tariffs and geopolitical tensions are significantly influencing the Advanced Biologics Manufacturing Market, particularly in East Asia. Japan and South Korea, with their robust technological infrastructure, are enhancing domestic biologics capabilities to mitigate reliance on foreign imports amid trade uncertainties. China is accelerating its strategic pivot towards self-sufficiency, investing heavily in biomanufacturing infrastructure to counteract export restrictions. Taiwan, while a critical player in biologics innovation, faces geopolitical vulnerabilities due to its proximity to China. The parent market is witnessing robust growth driven by rising demand for biologics, yet supply chain disruptions and tariff-induced cost pressures persist. By 2035, the market is expected to expand significantly, contingent upon regional collaborations and resilient supply networks. Middle East conflicts may exacerbate global energy costs, indirectly affecting manufacturing expenses and supply chain logistics.

Key Trends and Drivers:

The Advanced Biologics Manufacturing Market is experiencing robust growth, fueled by the increasing prevalence of chronic diseases and the rising demand for personalized medicine. Key trends include advancements in cell and gene therapy manufacturing technologies, which are enhancing production efficiencies and reducing costs. Regulatory agencies are also streamlining approval processes, encouraging innovation and expediting the market entry of new biologics. Biopharmaceutical companies are investing heavily in research and development to create novel biologic products, further driving market expansion. The growing trend of outsourcing manufacturing processes to specialized contract development and manufacturing organizations (CDMOs) is also noteworthy. This allows companies to focus on core competencies while leveraging the expertise and infrastructure of CDMOs. Moreover, the adoption of single-use technologies is gaining traction, offering flexibility and reducing contamination risks. The integration of artificial intelligence and machine learning in biologics manufacturing is optimizing production processes and enhancing product quality. As a result, the market is poised for substantial growth, with numerous opportunities for companies that innovate and adapt to these evolving trends.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Component
• 2.9 Key Market Highlights by Deployment

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Recombinant Proteins
  • 4.1.2 Monoclonal Antibodies
  • 4.1.3 Cell Therapy
  • 4.1.4 Gene Therapy
  • 4.1.5 Vaccines
  • 4.1.6 Antibody Drug Conjugates
  • 4.1.7 Biosimilars
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Bioreactors
  • 4.2.2 Centrifuges
  • 4.2.3 Chromatography Systems
  • 4.2.4 Filtration Systems
  • 4.2.5 Single-use Systems
  • 4.2.6 Cell Culture Media
  • 4.2.7 Buffers and Reagents
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Contract Manufacturing
  • 4.3.2 Process Development
  • 4.3.3 Analytical Testing
  • 4.3.4 Regulatory Compliance
  • 4.3.5 Quality Assurance
  • 4.3.6 Supply Chain Management
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Upstream Processing
  • 4.4.2 Downstream Processing
  • 4.4.3 Continuous Manufacturing
  • 4.4.4 Single-use Technology
  • 4.4.5 Automation
  • 4.4.6 Process Analytical Technology
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Cardiovascular Diseases
  • 4.5.3 Neurological Disorders
  • 4.5.4 Infectious Diseases
  • 4.5.5 Autoimmune Diseases
  • 4.5.6 Metabolic Disorders
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharmaceutical Companies
  • 4.6.2 Biotechnology Companies
  • 4.6.3 Research Institutes
  • 4.6.4 Contract Research Organizations
  • 4.6.5 Academic Institutions
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Fermentation
  • 4.7.2 Purification
  • 4.7.3 Formulation
  • 4.7.4 Filling
  • 4.7.5 Lyophilization
  • 4.7.6 Packaging
• 4.8 Market Size & Forecast by Component (2020-2035)
  • 4.8.1 Raw Materials
  • 4.8.2 Consumables
  • 4.8.3 Equipment
  • 4.8.4 Software
• 4.9 Market Size & Forecast by Deployment (2020-2035)
  • 4.9.1 In-house
  • 4.9.2 Outsourced
  • 4.9.3 Hybrid

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Process
    • 5.2.1.8 Component
    • 5.2.1.9 Deployment
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Process
    • 5.2.2.8 Component
    • 5.2.2.9 Deployment
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Process
    • 5.2.3.8 Component
    • 5.2.3.9 Deployment
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Process
    • 5.3.1.8 Component
    • 5.3.1.9 Deployment
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Process
    • 5.3.2.8 Component
    • 5.3.2.9 Deployment
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Process
    • 5.3.3.8 Component
    • 5.3.3.9 Deployment
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Process
    • 5.4.1.8 Component
    • 5.4.1.9 Deployment
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Process
    • 5.4.2.8 Component
    • 5.4.2.9 Deployment
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Process
    • 5.4.3.8 Component
    • 5.4.3.9 Deployment
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Process
    • 5.4.4.8 Component
    • 5.4.4.9 Deployment
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Process
    • 5.4.5.8 Component
    • 5.4.5.9 Deployment
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Process
    • 5.4.6.8 Component
    • 5.4.6.9 Deployment
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Process
    • 5.4.7.8 Component
    • 5.4.7.9 Deployment
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Process
    • 5.5.1.8 Component
    • 5.5.1.9 Deployment
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Process
    • 5.5.2.8 Component
    • 5.5.2.9 Deployment
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Process
    • 5.5.3.8 Component
    • 5.5.3.9 Deployment
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Process
    • 5.5.4.8 Component
    • 5.5.4.9 Deployment
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Process
    • 5.5.5.8 Component
    • 5.5.5.9 Deployment
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Process
    • 5.5.6.8 Component
    • 5.5.6.9 Deployment
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Process
    • 5.6.1.8 Component
    • 5.6.1.9 Deployment
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Process
    • 5.6.2.8 Component
    • 5.6.2.9 Deployment
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Process
    • 5.6.3.8 Component
    • 5.6.3.9 Deployment
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Process
    • 5.6.4.8 Component
    • 5.6.4.9 Deployment
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Process
    • 5.6.5.8 Component
    • 5.6.5.9 Deployment

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Wu Xi Biologics
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Samsung Biologics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Lonza
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Boehringer Ingelheim Bio Xcellence
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Catalent
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Fujifilm Diosynth Biotechnologies
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 AGC Biologics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Cytiva
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Thermo Fisher Scientific
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Sartorius
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Bio NTech
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Biocon
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Abzena
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Rentschler Biopharma
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Wacker Biotech
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 KBI Biopharma
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Just Evotec Biologics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Ab Cellera Biologics
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Cognate Bio Services
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Eurofins CDMO
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us